Retatrutide, a groundbreaking dual-acting glucose-dependent incretin analog, represents a significant leap in peptide medicines for the treatment of type 2 diabetic conditions and, increasingly, excess adiposity. Unlike many existing therapeutic interventions, retatrutide integrates the actions of a GLP-1 receptor stimulant and a GIP receptor agoni